These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30422962)

  • 1. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
    Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
    Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
    Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
    Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
    Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
    Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
    Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
    Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
    Pellicelli AM; Montalbano M; Lionetti R; Durand C; Ferenci P; D'Offizi G; Knop V; Telese A; Lenci I; Andreoli A; Zeuzem S; Angelico M
    Dig Liver Dis; 2014 Oct; 46(10):923-7. PubMed ID: 24997638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
    Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    Lawitz E; Poordad F; Gutierrez JA; Kakuda TN; Picchio G; Beets G; Vandevoorde A; Van Remoortere P; Jacquemyn B; Luo D; Ouwerkerk-Mahadevan S; Vijgen L; Van Eygen V; Beumont M
    J Viral Hepat; 2017 Apr; 24(4):287-294. PubMed ID: 27878906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation.
    Musialik J; Kolonko A; Kwiecień K; Owczarek AJ; Więcek A
    Transpl Infect Dis; 2019 Jun; 21(3):e13090. PubMed ID: 30972854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
    Nada A; Abbasy M; Sabry A; Abdu Allah AM; Shehab-Eldeen S; Elnaidany N; Elimam H; Mohamed Ibraheem KI; Essa A
    Can J Gastroenterol Hepatol; 2020; 2020():1632959. PubMed ID: 32083035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
    Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D
    Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
    Rivero-Juarez A; Brieva T; Frias M; Rivero A
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):901-910. PubMed ID: 30058394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.